Physician profile
Thomas N Dewar
NPI 1811988587
$10,277.50
in general payments reported to CMS, 2019-2025
46 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $381 · 2021: $883 · 2022: $2,120 · 2023: $2,334 · 2024: $1,766 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,509 · Education: $29.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,508.62 |
| Education | $29.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,167.82 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,052.36 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $960.34 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $911.28 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $666.94 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $421.94 | 2021-2024 | Zeposia |
| Pfizer INC. | $362.66 | 2019-2024 | |
| Genzyme Corporation | $337.91 | 2022-2025 | |
| Lilly USA, LLC | $284.48 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $279.99 | 2019-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $254.24 | 2019-2024 | Linzess |
| Daiichi Sankyo INC. | $225.48 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $205.84 | 2019-2023 | Rebyota |
| Ethicon US, LLC | $182.92 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $180.35 | 2019-2025 | Ocaliva |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $177.08 | 2021-2024 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $154.23 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $134.73 | 2020-2023 | Cre Pro |
| Regeneron Healthcare Solutions, INC. | $123.88 | 2022-2025 | Dupixent |
| Organon LLC | $113.17 | 2021-2024 | Hadlima |
| Ardelyx, INC. | $106.49 | 2022-2023 | Ibsrela |
| Janssen Scientific Affairs, LLC | $99.24 | 2019-2024 | Stelara, Remicade, Tremfya |
| Redhill Biopharma INC. | $84.42 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $82.39 | 2024-2025 | Zenpep |
| Amgen INC. | $78.32 | 2023 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $77.41 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $59.73 | 2021-2022 | |
| Madrigal Pharmaceuticals | $51.15 | 2025 | Rezdiffra |
| Enterra Medical, INC. | $50.49 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $47.35 | 2024-2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $37.02 | 2023 | Idacio |
| Romark Laboratories, Lc | $36.82 | 2019-2020 | |
| Evoke Pharma, INC. | $33.74 | 2023-2024 | Gimoti |
| Celltrion USA INC. | $27.80 | 2023-2025 | Vegzelma, Yuflyma |
| Allergan, INC. | $25.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.45 | 2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $21.61 | 2025 | Terlivaz |
| Sandoz INC. | $20.84 | 2023 | Hyrimoz |
| Shionogi INC | $17.47 | 2019 | |
| Coloplast Corp | $17.23 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.58 | 2023 | |
| Concordia Pharmaceuticals INC. | $15.68 | 2019 | |
| Vyaire Medical, INC. | $13.03 | 2022 | |
| Medtronic, INC. | $12.70 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dewar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.